Background: Epidemiological studies have documented higher than expected comorbidity (or in some cases, inverse comorbidity) between schizophrenia and several autoimmune disorders. It remains unknown whether this comorbidity reflect shared genetic susceptibility loci.
BACKGROUND
Both schizophrenia and autoimmune diseases are complex disorders caused by multiple genetic and non-genetic risk factors. Schizophrenia is a severe mental disorder while autoimmune diseases are a clinical heterogeneous group of diseases with common underlying mechanisms related to an immune response against self. Recently, genome-wide association studies (GWAS) of large casecontrol samples have identified genome-wide significant SNPs implicating several candidate regions and genes for both autoimmune diseases and schizophrenia (1, 2) . Here, the most solid genetic finding for both disorders is that common variants in the major histocompatibility complex (MHC) on chromosome 6 confer risk of disease but with very different effect sizes (1, 3) . The MHC region contains multiple genes and extensive linkage disequilibrium (LD) which have made it difficult to identify the causal variants but the findings do, however, support the notion that similarly to autoimmune diseases, inflammatory processes might be involved in the pathogenesis of schizophrenia (4) (5) (6) (7) (8) 1) . The role of the immune system in the aetiology of schizophrenia is supported by prenatal infections particular during the second trimester increasing the risk of the disease in the offspring as well as insult of infectious agents during childhood (9, 10) .
There is mounting evidence for higher than expected comorbidity (or in some cases, inverse comorbidity) between schizophrenia and a number of autoimmune disorders both at the individual and familial level when compared to the general population (11) (12) (13) (14) which could reflect a common genetic basis. Several GWAS have with great success been carried out for both disorders thus; it seems evident to test for shared genetic susceptibility loci of common SNPs that might contribute to the observed comorbidity between autoimmune diseases and schizophrenia and point towards shared molecular pathways and mechanisms. 4 
AIM
In this study, we examine whether verified genome wide significant variants of autoimmune disorders confer risk of schizophrenia thereby supporting a common genetic basis.
MATERIALS AND METHODS
All SNPs showing genome wide association (P≤5.0x10 -8 ) to an autoimmune disease were extracted from the National Human Genome Research Institute (NHGRI) GWAS catalogue (15) (http://www.genome.gov/gwastudies/, March, 2015) . SNPs from GWAS based on subgroups of patients, case only studies, response to treatment, haplotype-based associations, or shared risk alleles between diseases were excluded from the analysis. Thus, a total of 714 unique SNPs (Supplementary Table 1 ) of 25 autoimmune disorders from GWAS of European, East Asian, and North India ancestry were included in the study (Table 1) .
We used summary statistics from the Psychiatric Genomics Consortium schizophrenia (PGC-SCZ) GWAS samples, a large collection of 36,989 cases with schizophrenia and 113,075 controls of European and East Asian descent (1) (available at http://www.med.unc.edu/pgc/down-loads) to examine whether these 714 SNPs were genome wide associated with schizophrenia. A more in depth description of the PGC-SCZ GWAS samples can be obtained from the original publication (1) .
Of the initial 714 SNPs, 706 were present in the PGC-SCZ GWAS samples either by its original refSNP ID reported in the NHGRI GWAS catalogue (N=629), by its current refSNP ID (N=62, retrieved from the file RsMergeArch downloaded at http://www.ncbi.nlm.nih.gov) or by a proxy SNP (N=15, using SNAP (16), 1000 Genomes Pilot 1, CEU reference panel, r 2 =0.1). The remaining 8 SNPs were not found in the 1000 Genomes/CEU reference panel.
The 706 aforementioned SNPs present in the PGC-SCZ GWAS samples were spread across nearly all chromosomes (except chromosome 13 and the Y chromosome) and 90 SNPs were found in the MHC region (the extended MHC region was defined as chr6:29,570,005-33,377,699, hg19 (17)).
By applying the same LD criteria as in (1) , 388 of the 706 analysed SNPs remained (1000 Genomes Pilot 1, CEU reference panel, r 2 =0.1 and a 500kb window).
In order to evaluate the robustness of our findings regarding the observed number of shared susceptibility loci between autoimmune diseases and schizophrenia, we first used the PGC-SCZ GWAS samples and randomly selected 706 SNPs 1000 times to estimate the expected number of SNPs that would be associated with schizophrenia by chance.
Second, we used the LD pruned version of the PGC-SCZ GWAS samples where SNPs within 500kb of, and in r 2 ≥0.1 with, another (more significant) SNP were discarded as described in (1) .
From this LD pruned dataset, we randomly extracted 388 SNPs 1000 times where the 388 SNPs correspond to the number of independent autoimmune loci tested for genome wide association to schizophrenia (as described above). The observed number of shared susceptibility loci between autoimmune diseases and schizophrenia found in this study were considered statistical significant if less than 5% of the number of randomly chosen loci were found with P≤5.0x10 -8 .
Third, we extracted and evaluated all SNPs within 50kb up-and downstream of the non-MHC gene BANK1 (chr4:102,711,764-102,995,969, hg19) that had previously been reported in GWAS of autoimmune diseases (P≤5.0x10 -6 ) (rs4522865 and rs13126505 both associated with systemic lupus erythematosus (SLE)) from the NHGRI catalogue. Regional association plot was generated using LocusZoom (18) and all analyses related to the study were carried out using the statistical program R ver3.1.3 (http://www.r-project.org/).
(TABLE 1 HERE PLEASE)

RESULTS
A total of 714 risk variants were selected from GWAS of 25 autoimmune disorders (Table 1 and supplementary Table 1 ) and evaluated for genome wide association to schizophrenia in the latest PGC-SCZ GWAS sample in order to identify shared genetic susceptibility loci (see Materials and Methods for details regarding the SNP selection). Here, 706 SNPs were present in the PGC-SCZ GWAS sample (corresponding to 388 independent genomic regions) and of these 16 variants were found genome wide associated with schizophrenia (P≤3.1x10 -8 , Figure 1 -2 and Table 2 ). Of the 16 identified genome wide associated variants 15 were present in the MHC region on chromosome 6p21.32-33 (strongest P=4.0x10 -21 ) while the last SNP was located in the non-MHC gene BANK1 at chromosome 4q24 (P=1.2x10 -8 ) ( Table 2) . To determine whether the 16 observed loci shared between autoimmune diseases and schizophrenia occurred more often than expected, we first sampled 706 SNPs from the PGC-SCZ GWAS dataset 1000 times (see methods). Here, we did not sample more than 8 loci showing genome wide association to schizophrenia from the 1000 permutations. However, as 15 of the 16 shared variants between schizophrenia and autoimmune diseases were situated in the MHC region with strong LD structures, we in addition found that the two shared independent loci at 6p21.32-33 and 4q24 showed a considerable trend toward significance since 5.5% of the 388 randomly drawn SNPs from the LD pruned PGC-SCZ GWAS sample had P≤5x10 -8 ( Figure 3 ).
None of the neighbouring SNPs that had previously been associated with an autoimmune disease (SLE) positioned in the non-MHC gene BANK1 showed additional association to schizophrenia in the PGC-SCZ GWAS samples (rs4522865, P=5.3x10 -2 and rs10516487, P=1.7x10 -2 , Figure 4 and Supplementary Table 2 ).
(TABLE 2 AND FIGURE 1-4 HERE PLEASE)
CONCLUSSION Several epidemiological studies have shown that autoimmune diseases occur more frequently in patients suffering from schizophrenia than in the general population (11) (12) (13) (14) , however, no studies have addressed whether this could reflect shared genetic susceptibility loci between the diseases.
This study aimed to make a comprehensive assessment of the genetic overlap of common SNPs between the two epidemiologically related diseases by investigating whether genome wide associated variants originally identified from GWAS of autoimmune diseases were genome wide associated with schizophrenia using the largest GWAS samples of schizophrenia to date (1) . Several aspects of our work merit further discussion.
First, we identified two independent susceptibility loci at 6p21.32-33 and 4q24 shared by specific autoimmune diseases and schizophrenia (Table 2) ; however, when compared to randomly selected SNPs the number of shared loci were only marginally significant (P=0.055) ( Figure 3 ). Thus, common SNPs captured as significant in current GWAS only contribute with little effect to the autoimmune comorbidity among patients with schizophrenia that could instead be explained by non-significant or rare variants interacting with non-genetic factors which have so far not been addressed in the literature. However, as the GWAS sample size continue to grow it is likely that more shared susceptibility loci of common SNPs between schizophrenia and autoimmune diseases will be discovered.
Second, the MHC region on chromosome 6 is a universal genetic susceptibility region for all autoimmune diseases studied in addition to schizophrenia and the number of shared MHC loci found in this study, ensured the reliability of our findings. However, the magnitude of effect for each shared risk variants in the MHC region was markedly different between autoimmune disease and schizophrenia (Table 2) Fourth, several autoimmune disorders have in nation-wide population based register studies been associated with schizophrenia including the majority of the autoimmune diseases that were found to share risk variants with schizophrenia in this study (12, 13) . In addition, we identified shared loci with opposite directions for schizophrenia contradicting the epidemiological observations (e.g. autoimmune hepatitis and celiac disease) (12,13) and we did not exclusively find that the at-risk variants of rheumatoid arthritis are protective of schizophrenia as would be expected based on both epidemiological and genetic studies (12, 13, 20, 21) . In summary, by merging GWAS data from multiple autoimmune diseases and schizophrenia we were not able to show that common SNPs significantly contribute to the observed comorbidity between the two epidemiologically related diseases. 
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Supplementary table 1. The 714 genome wide associated SNPs from autoimmune diseases included in the study
